141 related articles for article (PubMed ID: 21190427)
1. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
[No Abstract] [Full Text] [Related]
2. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.
Sonoki T; Li Y; Miyanishi S; Nakamine H; Hanaoka N; Matsuoka H; Mori I; Nakakuma H
Int J Hematol; 2009 Apr; 89(3):400-402. PubMed ID: 19330555
[No Abstract] [Full Text] [Related]
4. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
5. [Richter syndrome: report of a case].
Chen DB; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):487-8. PubMed ID: 21055184
[No Abstract] [Full Text] [Related]
6. [Intravascular lymphoma treated with anti CD20 monoclonal antibodies. Report of one case].
Alfaro J; Espinoza A; Manŕiquez M; Moyano L; González N; Larrondo M; Figueroa G
Rev Med Chil; 2004 Nov; 132(11):1403-6. PubMed ID: 15693204
[TBL] [Abstract][Full Text] [Related]
7. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
[No Abstract] [Full Text] [Related]
8. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.
Micallef IN; Kirk A; Norton A; Foran JM; Rohatiner AZ; Lister TA
Blood; 1999 Apr; 93(7):2427-8. PubMed ID: 10215354
[No Abstract] [Full Text] [Related]
9. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
10. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
Kunzmann V; Ruediger T; Hallek M; Mueller-Hermelink HK; Wilhelm M
Blood; 2001 Sep; 98(6):1991-2. PubMed ID: 11565541
[No Abstract] [Full Text] [Related]
12. [Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Dong W; Cao L; Wang DS
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):270-2. PubMed ID: 21616007
[No Abstract] [Full Text] [Related]
13. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.
Matteucci P; Magni M; Di Nicola M; Carlo-Stella C; Uberti C; Gianni AM
Blood; 2002 Aug; 100(3):1104-5. PubMed ID: 12150156
[No Abstract] [Full Text] [Related]
14. CD20-negative relapse after (131)I-anti-CD20 therapy.
Venugopal P; Leslie WT; O'Brien T; Gregory SA
J Clin Oncol; 1999 Nov; 17(11):3692-3. PubMed ID: 10550173
[No Abstract] [Full Text] [Related]
15. Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab.
Voigtländer C; Harrer T; Schneider L; Schulze-Koops H; Niedobitek G; Lüftl M
Int J Dermatol; 2005 Nov; 44(11):976-8. PubMed ID: 16336543
[No Abstract] [Full Text] [Related]
16. Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab.
Linden MA; Bachanova V; Sachs Z; Young JA; Singleton TP; Ustun C
Leuk Lymphoma; 2013 Jan; 54(1):174-6. PubMed ID: 22568510
[No Abstract] [Full Text] [Related]
17. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-induced tumor progression: does it really happen?
Ozguroglu M; Turna H
Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
[TBL] [Abstract][Full Text] [Related]
19. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
20. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.
Antonini G; Cox MC; Montefusco E; Ferrari A; Conte E; Morino S; Latino P; Trasimeni G; Monarca B
J Neurooncol; 2007 Jan; 81(2):197-9. PubMed ID: 16937012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
